

Theoretical simulations for innovative nuclear medicine applications: cyclotron production of the theranostic radionuclides ^{47}Sc and ^{155}Tb




Francesca Barbaro

























NUCSYS - CSN4

REMIX - CSN5

SPES_MED - CSN3








THERANOSTICS

therapy + diagnosis

What we see is what we treat = personalized treatment






What type of radionuclides
are interesting for medical
purposes?

half-life & decay mode

**quantity & quality
(medical standards)**

feasible production routes for **^{47}Sc** and **^{155}Tb**



Theoretical calculations

Radionuclidic purity



activity



Bateman eq



rate




cross section



$$RNP = \frac{A_{47Sc}(t)}{\sum_{xx} A_{xxSc}(t)}$$

MAIN ISSUE:

**CONTAMINANTS,
radioisotopes that
affect the purity**






TALYS code

cross section


OPTIMIZATION

by GENETIC ALGORITHM



p-⁴⁹Ti



d-⁴⁹Ti






p-⁵⁰Ti




MAXIMIZE ⁴⁷Sc
MINIMIZE contaminants


p-⁴⁹Ti





d-⁴⁹Ti



Radionuclidic Purity



p-⁵⁰Ti



MAXIMIZE ⁴⁷Sc
MINIMIZE contaminants



PATENT




*"Metodo per produzione di **Sc-47** ad alta purezza con ciclotroni ad energie intermedie (35 MeV) attraverso un **bersaglio multistrato**"*

Patent application No. 102023000018477, deposited on 08/09/2023. Patent owner: INFN (Istituto Nazionale di Fisica Nucleare), inventors: Luciano Canton, Francesca Barbaro, Lucia De Dominicis, Liliana Mou, Gaia Pupillo

**Proton-induced production of the theranostic ^{47}Sc radionuclide:
nuclear cross-section measurements and dosimetric analysis**

Poster by Lucia De Dominicis

4 levels of ^{155}Gd -enrichments: 91.9%, 98%, 99%, 100%



A maximum 2% content of ^{156}Gd
in the target guarantees a **RNP** in
compliance with the clinical standards

Projects:

REMIX
METRICS
CUPRUM-TTD
NUCSYS
SPES_MED
APHRODITE-155 (PRIN)
CLOUDVENETO COMPUTING

Thanks to:

L. Canton (INFN PD)
Y. Lashko (INFN PD)
L. Zangrando (INFN PD)
L. De Nardo (UNIPD – INFN PD)
L. Meléndez-Alafort (IOV)
G. Pupillo (INFN LNL)
L. Mou (INFN LNL)
L. De Dominicis (UNIPD – INFN LNL)